# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2015 Earnings Results

**Report date:** 2015-08-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2015

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.81%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.89 | N/A | +59.67% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized a strong market position but did not provide specific guidance.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on innovation and maintaining our market position.

### Guidance Changes

No guidance data is available for future quarters.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and profitability, which likely contributed to the stock's 4.81% increase. Investors responded positively to the earnings surprise, reflecting confidence in the company's financial health. However, the lack of revenue details and future guidance may leave some uncertainty about long-term growth prospects.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2015_